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Antiviral cytotoxic T-cells are critical for control of lymphoctytic choriomeningitis virus (LCMV) infection in mice. In H-2b
mice, the antiviral response is directed against three Db-restricted epitopes in the viral nucleoprotein (NP396-404) and
glycoprotein (GP276-286 and GP33-41). Our present data revealed a clear hierarchy among these three epitopes, in which
NP396-404 is immunodominant, followed by GP33-41 and GP276-286, respectively. In order to identify additional CTL
epitopes in the LCMV nucleoprotein and glycoprotein, we used the motifs for Db- and Kb-binding peptides, combined with
MHC class I-binding assays. Out of 23 Db motif-fitting peptides, we identified 4 Db binders, one of which (GP92-101) turned
out to be a new CTL epitope. Among 28 Kb motif-fitting peptides, 12 bound Kb, and one of these (NP205-212) was a CTL
epitope. Both newly identified CTL peptides were recognized by LCMV-immune splenocytes after secondary in vitro
stimulation. Both peptides bound their MHC class I molecules with intermediate affinity (470 and 170 nM for GP92-101 and
NP205-212, respectively). Responses against these peptides were weaker than the responses against the three major
epitopes. None of the high affinity binders were new epitopes, suggesting that high affinity binders are either immunodom-
inant epiitopes or no epitopes at all. Thus, analysis of 51 Kb and Db motif-fitting peptides yielded 2 new, subdominant epitopes.
Immunization of C57BL/6 mice with these peptides, or with vaccinia virus recombinants expressing these epitopes as
minigenes, protected against chronic LCMV infection, demonstrating that immunization with subdominant epitopes can
confer protection against chronic viral infection. © 1998 Academic Press
INTRODUCTION
Lymphocytic choriomeningitis virus (LCMV) induces a
potent antiviral immune response in its murine natural
host. Antiviral CD81 cytotoxic T lymphocytes (CTLs) are
crucial for control of the viral infection. Through their
T-cell receptors (TCR), CTLs recognize small antigenic
peptides that are associated with major histocompatabil-
ity complex (MHC) class I molecules (Schumacher et al.,
1991; Townsend and Bodmer, 1989; Van Bleek and Na-
thenson, 1990). In the case of LCMV infection in mice of
the H-2b haplotype (e.g., C57BL/6 mice), the antiviral
response is largely directed against three dominant
epitopes, i.e., residues 396–404 from the nucleocapsid
protein (FQPQNGQFI), residues 33–41 from the glycopro-
tein (KAVYNFATC), and residues 276–286 from the glyco-
protein (SGVENPGGYCL) (Gairin et al., 1995; Klavinskis
et al., 1990; Oldstone et al., 1988; Schulz et al., 1989; Selin
et al., 1996). These three peptides are presented by the
Db MHC class I molecule and are therefore referred to as
Db-restricted.
In several different experimental systems, it has been
shown that there is a hierarchy in the epitope specificity
of MHC class I-restricted responses (Feltkamp et al.,
1995; Jameson and Bevan, 1992; Oukka et al., 1994; Van
der Most et al., 1996; Vitiello et al., 1996). CTL epitopes
can be dominant, subdominant, or cryptic. Several differ-
ent factors can contribute to the dominance or subdomi-
nance of a potential epitope, such as (i) the intracellular
processing of the antigenic peptide, (ii) its MHC class
I-binding affinity, and (iii) the TCR repertoire. In the
present study, we have investigated the existence of
LCMV-specific, H-2b-restricted subdominant responses.
Eventually, identification of subdominant epitopes could
be a first step toward the development of therapeutic
vaccination protocols, i.e., immunization to combat an
established infection.
A proven strategy to identify new CTL epitopes, is to
use allele-specific sequence motifs for MHC class I-
binding peptides, combined with MHC-binding assays
(Kast et al., 1994; Van der Most et al., 1996; Vitiello et al.,
1996). Allele-specific epitope motifs, first discovered after
sequence analysis of pools of naturally processed pep-
tides eluted from class I molecules, have now been
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identified for several human as well as murine class I
alleles. They usually consist of two or more conserved
anchor residues and comprise between 8 and 11 amino
acids (Rammensee et al., 1995). We have used the motifs
described for the Db and Kb class I alleles to search for
new LCMV CTL epitopes. Motif-fitting peptides were
synthesized and tested for MHC class I binding using
recently developed Db- and Kb-binding assays (Vitiello et
al., 1996). This approach resulted in the identification of
four Db-binding peptides and twelve Kb binders. Among
these peptides, two were found to be new, subdominant
epitopes; both peptides are recognized by antiviral CTL
after secondary stimulation and were shown to confer
protective immunity against chronic viral infection.
MATERIALS AND METHODS
Mice
Five- to eight-week-old female C57BL/6 mice were
purchased from The Jackson Laboratory (Bar Harbor,
ME) or bred at our colony at the University of California
at Los Angeles.
Virus
LCMV strain Armstrong CA1371 (Ahmed et al., 1984)
and its derivative clone 13 (Ahmed et al., 1991, 1984; King
et al., 1990; Matloubian et al., 1993) were used in this
study. LCMV clone 13 was isolated from the spleens of
BALB/c LCMV carrier mice infected at birth with Arm-
strong. LCMV-immune mice were obtained by infecting
mice ip with 2 3 105 PFU of LCMV Armstrong. Immune
mice were used in experiments at .30 days post infec-
tion (p.i.). For challenge experiments, mice were infected
iv with 1.5 3 106 PFU of LCMV clone 13.
Cell lines
MC57 cells (H-2b) were used as targets in cytotoxicity
assays. The mouse lymphoma line EL-4 was used as a
source of Db and Kb class I molecules. MC57 cells were
used as target cells rather than EL-4 cells, since MC57
cells gave consistently better results, i.e., higher levels of
51Cr release than EL-4, using the same effector cells.
MHC I expression levels in MC57 cells were similar, if
not higher, than in EL-4 cells. Vero cells were used for
virus titration. MC57 and EL-4 cells were maintained in
RPMI 1640 medium supplemented with 10% heat-inacti-
vated fetal calf serum (FCS), 2 mM L-glutamine, and
antibiotics. Vero cells were maintained in EMEM supple-
mented with 10% FCS, 2mM L-glutamine, and antibiotics.
Large quantities of EL-4 cells were grown in spinner
cultures.
Affinity purification of H-2b molecules and MHC
Class I peptide-binding assay
H-2b molecules were purified from EL-4 cell lysates by
affinity chromatography, as described previously (Sette
et al., 1994; Vitiello et al., 1996) using monoclonal anti-
bodies Y3 (anti H-2Kb) or 28-14-8s (anti H-2Db). H-2Db
and H-2Kb peptide-binding assays were done as previ-
ously described (Sette et al., 1989; Vitiello et al., 1996).
The radiolabeled probes utilized, and their average
IC50s in the respective assays, were a P73Y analog
(SGPSNTYPEI, 4.4 nM) of the adenovirus E1A epitope
(Kast et al., 1989) for Db and the VSV NP52-59 epitope
(RGYVFQGL, 3.1 nM) (Van Bleek and Nathenson, 1990)
for Kb.
Peptide synthesis
Peptides were either synthesized at Cytel as previ-
ously described (Ruppert et al., 1993) or, for large epitope
libraries, purchased as crude material from Chiron
Mimotopes (Chiron Corp., San Diego, CA). Peptides syn-
thesized at Cytel were purified to .95% homogeneity
by reverse-phase HPLC. The purity of the synthetic pep-
tides was assayed on an analytical reverse-phase col-
umn, and their composition was ascertained by amino
acid analysis, sequencing, and/or mass spectrometry
analysis.
Peptide immunization
Lipidated peptides, comprising a CTL epitope co-
valently attached to a T-helper epitope (chicken ovalbu-
min 323-336, ISQAVHAAHAEINE) and a lipid moiety (Vi-
tiello et al., 1995), were dissolved in PBS (10 nmol in 100
ml PBS) and injected sc at the base of the tail. Mice were
challenged with 1.5 3 106 PFU LCMV clone 13 at least 15
days after immunization.
Construction of vaccinia viruses encoding LCMV CTL
epitopes
Oligonucleotides encoding the relevant epitopes, pre-
ceded by an ATG start codon, and with a termination
codon immediately following the open-reading frame,
were synthesized (Gibco BRL), and were cloned into a
vaccinia transfer plasmid downstream of the p7.5 vac-
cinia promoter. Using these transfer plasmids, vaccinia
recombinants were generated by standard procedures
(Mackett et al., 1984; Whitton et al., 1988), and were
subjected to four rounds of plaque purification. Virus
stocks were grown in HeLa cells. The DNA sequence of
each insert was confirmed by PCR sequencing of the
recombinant virus DNA as previously described (Sheng
et al., 1993). The epitope sequences, including the me-
thionine initiator, are MYTVKYPNL (NP205-212), MC-
SANNSHHYI (GP92-101), and MGYCLTKWMI (GP283-
291). The latter sequence, encompassing a Kd-restricted
LCMV epitope (Van der Most et al., 1997, 1996) was used
to construct the control vaccinia virus recombinant.
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Immunization with vaccinia virus recombinants
Mice were immunized with vaccinia virus recombi-
nants by ip injection of 2 3 106 PFU virus. Immunized
mice were challenged with 1.5 3 106 PFU LCMV at least
30 days after the vaccinia virus infection.
Cr-release assays and secondary in vitro stimulation
Effector cells were tested for their cytolytic activity in a
standard 6 h 51Cr-release assay as described previously
(Van der Most et al., 1996). To obtain secondary CTLs,
spleens from LCMV-immune mice were removed, eryth-
rocytes were lysed by treatment with NH4Cl, and a sin-
gle-cell suspension of splenocytes was cultured for 5
days at a concentration of 4 3 106 cells/ml in the pres-
ence of 1 mg/ml free peptide in RPMI 1640 supplemented
with 10% FCS, 4 mM L-glutamine, 50 mM b-mercapto-
ethanol, and antibiotics.
RESULTS
Identification and binding capacity of LCMV-derived
Db and Kb peptides
To identify new H-2b-restricted LCMV epitopes, we
have adapted the sequence motifs described for Db- and
Kb-restricted CTL epitopes (Falk et al., 1991; Rammensee
et al., 1995; Saito et al., 1993), to be somewhat more
permissive. This was done based on the observations
that differently sized peptides as well as peptides with
different, yet chemically similar, C-terminal anchor resi-
dues frequently still bind MHC class I molecules with
good affinity (Kast et al., 1994; Kubo et al., 1994; Sidney et
al., 1995), Thus, in the case of Db, we have considered
10-mer peptides N5(MI)10, besides the canonical nonam-
ers N5(MI)9. Also, we have utilized the motif N5(LV)9,
which allows for C-terminal residues chemically similar
to the standard M or I. In the case of Kb, the (YF)5(LM)8
motif was extended to also allow for V or I residues at the
C-terminus. Also, the binding potential of a size variant of
the canonical motif was explored by utilizing the
(YF)5(LM)9 motif.
Screening of the amino acid sequences of the LCMV
nucleoprotein (NP) and glycoprotein (GP) yielded 23 pep-
tides carrying the Db motif (Table 1) and 28 peptides
containing the Kb motif (Table 2). All motif-fitting peptides
were synthesized and tested for MHC class I binding
using recently developed binding assays specific for the
Db and Kb class I alleles (Vitiello et al., 1996). These
TABLE 1
Db Binding of LCMV Peptides
Peptidea Sequencea
Binding capacity
IC50 (nM)
b
NP396-404 FQPQNGQFI 4.4
GP276-286 SGVENPGGYCL 52
GP33-41 KAVYNFATC 5429
GP33-43 KAVYNFATCGI 776
GP392-400 WLVTNGSYL 128
GP92-101 CSANNSHHYI 470
GP110-118 LTFTNDSII 1462
NP550-558 FRGPNVVTL 3455
NP166-175 SLLNNQFGTM 6333
NP207-215 VKYPNLNDL .10000
NP266-274 IKPSNSEDL .10000
NP45-53 SEVSNVQRI .10000
NP464-472 LDSQNRKDI .10000
NP83-91 TSKKNVLKV .10000
NP45-54 SEVSNVQRIM .10000
NP255-264 LDGGNMLESI .10000
NP293-302 VGDRNPYENI .10000
NP372-381 GIDPNAPTWI .10000
NP384-393 EGRFNDPVEI .10000
GP117-125 IISHNFCNL .10000
GP321-329 LIDYNKAAL .10000
GP16-24 DEVINIVII .10000
GP160-168 CDFNNGITI .10000
GP150-158 RGNSNYKAV .10000
GP411-420 QEADNMITEM .10000
GP159-168 SCDFNNGITI .10000
a The known, dominant epitopes are shown in bold face.
b Peptide binding is expressed as the IC50, as described under
Materials and Methods.
TABLE 2
Kb Binding of LCMV Peptides
Peptide Sequence
Binding capacity
IC50 (nM)
a
GP70-77 GVYQFKSV 10
NP223-230 TSYQYLII 34
NP356-364 VGLSYSQTM 64
GP4-11 IVTMFEAL 67
NP205-212 YTVKYPNL 170
GP118-125 ISHNFCNL 371
GP45-52 ALISFLLL 933
GP256-264 KTKFFTRRL 1143
GP221-228 SQTSYQYL 1866
GP448-455 LVSIFLHL 2800
GP96-103 NSHHYISM 3111
NP121-129 ASGVYMGNL 4000
NP491-498 VWDKYGWL .10000
GP371-378 NYSKFWYL .10000
GP40-47 TCGIFALI .10000
GP264-272 LAGTFTWTL .10000
NP168-175 LNNQFGTM .10000
NP40-47 NGLDFSEV .10000
NP295-302 DRNPYENI .10000
NP236-244 NISGYNFSL .10000
NP295-303 DRNPYENIL .10000
NP300-308 ENILYKVCL .10000
NP418-426 QDSKYSHGM .10000
GP311-318 HDAEFCDM .10000
GP64-71 GPDIYKGV .10000
GP151-158 GNSNYKAV .10000
GP130-138 NKKTFDHTL .10000
GP311-319 HDAEFCDML .10000
a Peptide binding is expressed as the IC50, as described under
Materials and Methods.
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assays are based on competition for binding of the
peptide of interest with a radiolabeled standard peptide
that binds the class I molecule in question with high
affinity (Sette et al., 1994). The concentration necessary
to inhibit binding of the labeled standard peptide to
solubilized class I molecules by 50%, referred to as the
inhibitory concentration 50% (IC50 (nM), is measured and
approximates the affinity (Kd) of a given peptide–MHC
interaction. Sensitive Db- and Kb-binding assays were
developed using a P73Y analog (SGPSNTYPEI) of the
adenovirus E1A epitope (Kast et al., 1989), and the VSV
NP52-59 (RGYVFQGL) epitope (Van Bleek and Nathen-
son, 1990) as radiolabeled ligands, respectively (Vitiello
et al., 1996). Using these assays, IC50 values for each of
the motif-fitting LCMV peptides and the three known
epitopes were measured in two to four independent
experiments. As shown in Table 2, among the three
known Db-restricted epitopes, NP396-404 was the best
binder, followed by GP276-286 and GP33-41. A C-terminal
extension of two amino acids, yielding GP33-43, im-
proved MHC binding considerably, confirming earlier
work by Gairin et al. (Gairin et al., 1995). Out of the 23
new Db motif-containing peptides, two bound MHC with
intermediate affinity (IC50, 50–500 nM) and two bound
with low affinity (IC50, 500–5000 nM) (Table 1). The remain-
ing 19 peptides did not bind Db. Out of 28 Kb motif-fitting
peptides, we found two high-affinity binders (IC50 , 50
nM), four intermediate-affinity binders, and six low-affin-
ity binders (Table 2). Note that a considerable number of
MHC-binding peptides bears extended motifs. In fact,
among the three best Kb binders, two have a noncanoni-
cal C-terminus (GP70-77 and NP223-230) and one is a
nonamer (NP356-364). Furthermore, both Db binders
bear extended motifs: GP392-400 has a noncanonical
C-terminus and GP92-101 is a 10-mer.
In summary, the data presented herein indicate that
(including the low-affinity binders) 16 potential H-2b-re-
stricted CTL epitopes, in addition to the 3 known
epitopes, exist in the LCMV glycoprotein and nucleopro-
tein sequences.
Recognition of the new MHC-binding peptides by
LCMV-specific CTLs
To investigate whether any of the Db- or Kb-binding
peptides participate in the antiviral CTL response in a
natural LCMV infection in mice and are in fact CTL
epitopes, we studied whether these peptides are recog-
FIG. 1. Primary ex vivo antiviral CTL responses in C57BL/6 mice are primarily directed against the three dominant epitopes, NP396-404, GP33-43,
and GP276-286. MC57 target cells were infected with LCMV clone 13 (m.o.i. 5 1) or coated with the different peptides (1 mg/ml). The restriction
elements of the peptides (Db or Kb) are indicated. Specific lysis in the absence of peptide or LCMV infection has been subtracted from each value.
Different effector/target (E/T) ratios are indicated.
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nized by primary antiviral CTLs. In these experiments we
used the two high- (GP70-77 and NP223-230) and six
intermediate-affinity binders (GP392-400, GP92-101,
NP356-364, GP4-11, NP205-212, and GP118-125) as well
as two low-affinity binders (GP45-52 and GP256-264). To
obtain primary antiviral CTLs, C57BL/6 mice (H-2b) were
infected with 2 3 105 PFU LCMV strain Armstrong. In
adult mice, this strain causes an acute infection that is
usually cleared within 8 days. Splenocytes of infected
mice were harvested at eight days p.i. Next, peptide-
specific CTL activity of the LCMV-primed CTLs was mea-
sured in a direct ex vivo 51Cr-release assay on syngeneic
target cells (MC57), which were coated with the different
Db- and Kb-binding peptides. As controls, CTL activities
were measured on target cells coated with the dominant
peptides (NP396-404, GP33-43, and GP276-286), on
LCMV-infected targets, and on uncoated/uninfected tar-
gets. As shown in Fig. 1, the results clearly reveal a
hierarchy among the three major epitopes. NP396-404 is
immunodominant, GP33-43 is somewhat weaker, and
GP276-286 is the weakest of the three dominant
epitopes. However, none of the new Db- or Kb-binding
peptides (with the possible exception of NP205-212 and
GP118-125) sensitized target cells for lysis, indicating
that these peptides do not play a major role in the
primary antiviral response. This is consistent with the
notion that the antiviral response is largely directed
against the NP396-404, GP33-43, and GP276-286
epitopes.
It is conceivable, however, that the dominant CTL
response clears the virus so effectively that antigen lev-
els become limiting before CTLs recognizing less-dom-
inant epitopes have the opportunity to expand. To exam-
ine this possibility, we measured secondary CTL
responses after in vitro stimulation of LCMV-immune
splenocytes (i.e., spleen cells from mice that had previ-
ously cleared an LCMV infection) with the different Db-
and Kb-binding peptides. Specific, low-frequency CTL
precursors could be amplified by this experimental ap-
proach. It is important to perform the secondary in vitro
stimulation with peptide rather than with LCMV-infected
cells, to avoid a strong bias toward the immunodominant
epitopes. Accordingly, splenocytes from LCMV-immune
C57/B6 mice were stimulated in vitro for 5 days with
FIG. 2. Peptide specificity of secondary antiviral CTL responses in C57BL/6 mice that cleared an acute LCMV infection. Secondary CTL were
obtained after in vitro stimulation of mouse spleen cells for 5 days with peptide (1 mg/ml). MC57 target cells were coated with the different peptides
(1 mg/ml). The restriction elements of the peptides (Db or Kb) are indicated. Specific lysis in the absence of peptide has been subtracted from each
value. Different effector/target (E/T) ratios are indicated. For GP70-77, GP4-11, and GP45-52 the E/T ratios used were 25:1, 8:1, and 2.5:1.
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peptide, after which lysis of targets coated with the
appropriate peptides was measured in a standard 51Cr-
release assay. As expected, stimulation of LCMV-im-
mune splenocytes with the immunodominant peptide
NP396-404 resulted in a strong, NP396-404-specific re-
sponse (Fig. 2). However, significant peptide-specific re-
sponses were also measured after stimulation with pep-
tides GP92-101 and NP205-212 (Fig. 2). Weak responses
could be measured against GP118-125. No responses
against any of the other peptides were detected. Peptide
dilution experiments, in which splenocytes were stimu-
lated with 1 mg/ml peptide and target cells were coated
with serial dilutions of peptide (from 1 mg/ml peptide
down to 1 pg/ml), yielded similar results, and, therefore,
the same hierarchy of epitopes (data not shown). Thus,
from the 10 MHC class I-binding peptides that we iden-
tified, 2 are clearly recognized during a natural LCMV
infection and therefore represent 2 new LCMV-derived
Db-restricted (GP92-101) and Kb-restricted (NP205-212)
CTL epitopes. GP118-125 could be an additional, Kb-
restricted, subdominant epitope. Stimulation of naive
splenocytes with NP205-212 or GP92-101 did not yield
any peptide-specific responses (data not shown), dem-
onstrating that the CTL activities measured after stimu-
lation of LCMV-immune splenocytes were indeed primed
by the LCMV infection. The low responses against GP92-
101 and NP205-212 (as compared to the dominant
epitopes, Fig. 1) indicate that these 2 peptides are sub-
dominant epitopes.
Immunization with subdominant epitopes protects
against persistent viral infection
Since 2 out of 10 MHC-binding peptides are recog-
nized by LCMV-primed CTLs after secondary stimulation
in vitro, we asked whether immunization with these
epitopes would induce effective antiviral CTLs; i.e., are
previously primed CTLs recognizing subdominant
epitopes able to control a subsequent viral challenge? To
evaluate epitope-specific immunity, C57BL/6 mice were
immunized with peptide or with vaccinia virus recombi-
nants expressing the subdominant epitopes as mini-
genes (see below). Immunized mice were subsequently
challenged with 1.5 3 106 PFU LCMV clone 13. LCMV
clone 13 is an Armstrong derivative that readily estab-
lishes a persistent infection in adult mice, unless antivi-
ral memory CTL precursors are present (Lau et al., 1994).
First, mice were immunized with the peptides NP396-
404, NP205-212, and GP92-101 or mock-immunized with
PBS. To enhance immunogenicity of the peptides, they
were administrated as lipopeptide HTL–CTL constructs
(Vitiello et al., 1995). The lipopeptide constructs consist
of the CTL epitope covalently linked to a T-helper epitope
and to a lipid moiety. The T-helper epitope used in this
study comprises residues 323–336 from chicken ovalbu-
min. Such lipopeptide constructs have been shown to be
excellent immunogens using hepatitis B virus CTL
epitopes (Vitiello et al., 1995). Two weeks after immuni-
zation, peptide and mock-immunized mice were chal-
lenged with 1.5 3 106 PFU LCMV clone 13 and virus titers
were determined 8 and 15 days later. As shown in Table
3, immunization with the dominant NP396-404 epitope
conferred excellent protection: immunized mice con-
trolled the infection within 8 days. Protection against
chronic infection was also observed for the subdominant
epitopes NP205-212 and GP92-101. For both peptides we
found that the two immunized mice had 10- to 100-fold
reduced titers at day 8 p.i. compared to those of mock-
immunized mice, and had cleared the infection by day 15.
None of the mock-immunized mice were able to control
the infection. Thus, immunization with subdominant
epitopes can confer protective immunity.
To further evaluate the potential of subdominant
epitopes to induce protective immunity, vaccinia recom-
TABLE 3
Vaccination with Subdominant CTL Epitopes Confers Protection
against Chronic LCMV Infection
Epitope Mouse No. Immunizationa
LCMV titer
in serum
(log10 PFU/ml)
Day 8 Day 15
MOCKb 1 PBS 4.7 4.9
2 PBS 4.7 5.2
3 control vvb 4.7 4.3
4 control vv 5.0 5.0
5 control vv 4.8 5.0
NP396-404 1 peptide 2.2 ,1.7
2 peptide ,1.7 ,1.7
3 peptide ,1.7 ,1.7
GP33-43 1 rec. vv ,1.7 ,1.7
2 rec. vv 1.7 ,1.7
3 rec. vv ,1.7 ,1.7
4 rec. vv ,1.7 ,1.7
NP205-212 1 peptide 3.8 ,1.7
2 peptide 3.3 ,1.7
3 rec. vv 2.9 ,1.7
4 rec. vv 2.0 ,1.7
5 rec. vv 2.9 ,1.7
6 rec. vv 2.6 ,1.7
7 rec. vv 2.2 ,1.7
GP92-101 1 peptide 2.5 ,1.7
2 peptide 3.9 2.3
3 rec. vv 5.0 5.0
4 rec. vv ,1.7 ,1.7
5 rec. vv 2.0 ,1.7
6 rec. vv 2.8 ,1.7
a C57BL/6 (H-2b) mice were immunized with peptide or with recom-
binant vaccinia viruses (rec. vv) as described under Materials and
Methods.
b Mock-immunized mice were injected either with PBS (Nos. 1 and 2)
or with a recombinant vaccinia virus (control vv) expressing the H-2d-
restricted LCMV epitope GP283-291 (Nos. 3–5) (van der Most et al.,
1996).
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binants that expressed GP92-101 and NP205-212 as
minigenes were generated (Whitton et al., 1993). As a
positive control, we used vaccinia virus recombinant
MG34 which expresses the strong Db-restricted epitope
GP33-43 (Whitton et al., 1993), and as the negative con-
trol we used a recombinant that expressed an H-2d-
restricted LCMV epitope (GP283-291) (Van der Most et
al., 1997, 1996). C57BL/6 mice were infected with 2 3 106
PFU recombinant vaccinia virus, and were challenged
with LCMV clone 13 at least 30 days later. As shown in
Table 3, mice immunized with recombinants expressing
GP33-43, NP205-212, and GP92-101 rapidly cleared the
virus, confirming the results of peptide immunization
studies. In the case of GP33-43 (the positive control),
serum virus titers were below the detection limit for three
out of four mice at day 8 pi. For the two subdominant
epitopes, NP205-212 and GP92-101, serum titers were
100- to 1000-fold reduced as compared to those of the
negative control at day 8 p.i. and were below detection
levels at day 15. Analysis of virus titers in different organs
at day 8 p.i. indicated that mice immunized with subdomi-
nant epitopes clear the infection with somewhat slower
kinetics than MG34 immunized mice (Table 4). Serum
titers in these mice were low and there was also a 10- to
1000-fold drop in virus levels in the different tissues.
DISCUSSION
In the present study, we have identified two new H-2b-
restricted, subdominant LCMV epitopes, i.e., the Db-re-
stricted epitope GP92-101 and the Kb-restricted epitope
NP205-212. Both peptides bind their restricting class I
molecules with intermediate affinity (IC50 values are 470
and 170 nM, respectively), induce protective immunity,
and are recognized by LCMV-primed CTLs after second-
ary in vitro stimulation of memory T-cells with peptide.
The Kb-binding peptide GP118-125 could be an additional
subdominant epitope, since weak responses against this
peptide could be detected. Our data also reveal a clear
hierarchy in antiviral responses in H-2b mice. In a direct
ex vivo cytotoxicity assay, NP396-404 is the immunodom-
inant epitope, followed by GP33-43 and GP276-286.
The identification of three (including GP118-125) new
subdominant CTL epitopes illustrates the value of com-
bining motif searches with MHC class I-binding assays.
As summarized in Table 5, analysis of 51 Db/Kb motif-
fitting peptides yielded two high-, six intermediate, and
eight low-affinity binders. Out of these 16 peptides, 3
were new CTL epitopes. In a previous study, we analyzed
34 Dd/Kd motif-fitting peptides, and found one high-, four
intermediate-, and five low-affinity binders; 2 of the 10
peptides were new CTL epitopes (Table 5) (Van der Most
et al., 1996). Thus, by combining motif searches with
MHC class I-binding assays new subdominant epitopes
can be readily identified, although a considerable num-
ber of peptides has to be tested. Strikingly, all new
subdominant epitopes are intermediate binders (Table
5), indicating that an IC50 value lower than 500 nM is
critical (Sette et al., 1994). On the other hand, high-affinity
binders tend to be either dominant epitopes, e.g., NP396-
404 (IC50, 4.4 nM) and the L
d-restricted immunodominant
LCMV epitope NP118-126 (IC50, 1.3 nM) (Van der Most et
al., 1996), or no epitopes at all, e.g., Kb binders GP70-77
TABLE 4
Vaccination with Subdominant Epitopes Confers Protection against Chronic Infection: Tissue Titers at Day 8 Postinfectiona
Epitope Mouse No.
LCMV titer in tissues (log10 PFU/ml or g of tissue)
Serum Spleen Liver Kidney Lung
MOCKb 1 5.8 6.3 6.9 6.6 7.8
2 5.8 6.0 6.5 6.3 8.0
3 5.5 6.8 7.7 6.6 7.7
4 5.5 6.3 7.3 6.0 7.0
GP33-43 1 ,1.7 2.0 ,1.7 3.6 2.3
2 ,1.7 ,1.7 ,1.7 3.0 2.0
3 ,1.7 ,1.7 ,1.7 3.0 2.8
4 ,1.7 ,1.7 ,1.7 2.0 2.6
NP205-212 1 1.7 3.8 3.0 2.8 5.0
2 3.0 3.8 3.6 3.6 .5.0
3 3.3 4.0 5.0 3.3 5.3
4 3.0 4.0 4.3 3.0 5.0
GP92-101 1 3.0 3.5 4.0 3.5 4.0
2 ,1.7 3.3 ,1.7 2.0 3.8
3 ,1.7 4.0 3.5 2.0 4.0
a C57BL/6 mice were immunized with recombinant vaccinia virus as described under Materials and Methods.
b Mock-immunized mice were injected with a control recombinant vaccinia virus, expressing the H-2d-restricted LCMV epitope GP283-291 (van der
Most et al., 1996).
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and NP223-230 (IC50, 10 and 34 nM, respectively) and the
Kd-binding LCMV peptide NP314-322 (IC50, 4.8 nM) (Van
der Most et al., 1996). Thus, subdominant epitopes are
most likely to be found among intermediate binders,
whereas the absence of epitopes among the new high-
affinity binders, GP70-77, NP223-230, and NP314-322
(Van der Most et al., 1996), probably reflects a hole in the
TCR repertoire or a processing problem.
Using a similar approach as described here, Oldstone
and co-workers identified 34 NP and GP peptides that fit
the Db—MHC class I-binding motif (Hudrisier et al.,
1996; Oldstone et al., 1995). They found that 3 of these
peptides, including GP92-101, bound Db. However, they
were not able to detect LCMV-specific CTL that recog-
nized GP92-101 and concluded that this viral peptide was
not a CTL epitope. The most likely explanation for this
result is the secondary CTL protocol used by these
investigators in which spleen cells from LCMV-infected
mice were restimulated with virus-infected cells for 5
days and then tested for cytolytic activity on peptide-
coated targets. Such conditions greatly favor the expan-
sion of CTL recognizing dominant epitopes and it is very
easy to miss subdominant responses after restimulation
with virus-infected cells. As pointed out previously, in
order to detect subdominant CTL responses, it is critical
to restimulate with the specific peptide (Van der Most et
al., 1996). The precursor frequency of GP92-101-specific
CTL in LCMV immune mice is 10- to 100-fold lower than
the precursor frequency of CTL specific for the dominant
epitopes (K. Murali-Krishna and R. Ahmed, unpublished
data) and therefore selective stimulation (i.e., with pep-
tide) is necessary to detect the subdominant GP92-101
response. A possible concern regarding CTL obtained by
peptide restimulation is whether these peptide-activated
CTL are ‘‘truly’’ virus specific and can recognize virus-
infected cells. In this study, we have shown that this is
indeed the case: not only do GP92-101-stimulated CTL
kill LCMV-infected targets, but, even more importantly,
vaccination with the GP92-101 epitope confers protective
immunity.
The fact that these epitopes do elicit protective immu-
nity makes them excellent candidates for therapeutic
immunization studies. Chronic LCMV infection in mice is
thought to result from the ‘‘exhaustion’’ (deletion) of
LCMV-specific CTLs following overwhelming antigenic
stimulation (Hotchin, 1971; Moskophides et al., 1993). It is
conceivable that CTLs recognizing subdominant
epitopes such as GP92-101 and NP205-212 may escape
deletion and could be activated once a chronic infection
is established. Also, variants of these peptides with dif-
ferent anchor residues could be explored for their use as
therapeutic vaccines. The potential of using epitope an-
alogs is illustrated in two recent studies, in which mel-
anoma-specific (Bakker et al., 1997) and influenza A-spe-
cific CTL epitopes were modified (Tourdot et al., 1997). In
both cases, replacements of the anchor residues re-
sulted in better MHC class I binding. In addition, immu-
nization with modified subdominant influenza A epitopes
induced strong protective immunity (Tourdot et al., 1997).
Thus, increasing MHC class I binding of the LCMV sub-
dominant epitopes described here and previously (Van
der Most et al., 1997, 1996) may increase the immunoge-
nicity of these epitopes and turn them into excellent
candidates for therapeutic vaccination studies.
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